Brokerages Anticipate SomaLogic, Inc. (NASDAQ:SLGC) to Announce -$0.15 Earnings Per Share

Equities research analysts predict that SomaLogic, Inc. (NASDAQ:SLGCGet Rating) will announce ($0.15) earnings per share for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for SomaLogic’s earnings, with the lowest EPS estimate coming in at ($0.17) and the highest estimate coming in at ($0.13). The company is expected to issue its next quarterly earnings results after the market closes on Monday, January 1st.

On average, analysts expect that SomaLogic will report full year earnings of ($0.69) per share for the current year, with EPS estimates ranging from ($0.80) to ($0.51). For the next financial year, analysts forecast that the firm will report earnings of ($0.67) per share, with EPS estimates ranging from ($0.80) to ($0.44). Zacks’ EPS averages are a mean average based on a survey of research firms that follow SomaLogic.

SomaLogic (NASDAQ:SLGCGet Rating) last posted its quarterly earnings results on Tuesday, March 29th. The company reported ($0.13) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.12) by ($0.01).

A number of brokerages recently commented on SLGC. Stifel Nicolaus began coverage on shares of SomaLogic in a research note on Tuesday, February 1st. They issued a “buy” rating and a $12.00 price objective on the stock. Zacks Investment Research cut shares of SomaLogic from a “hold” rating to a “sell” rating in a research note on Wednesday, April 20th. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the company. According to MarketBeat, SomaLogic presently has an average rating of “Buy” and an average target price of $16.25.

Shares of NASDAQ:SLGC traded up $0.23 on Monday, reaching $6.93. 784,932 shares of the company were exchanged, compared to its average volume of 1,076,658. SomaLogic has a 1-year low of $6.46 and a 1-year high of $14.72. The company has a 50-day moving average of $7.92 and a 200-day moving average of $9.96.

Several institutional investors have recently added to or reduced their stakes in SLGC. Wolverine Asset Management LLC acquired a new stake in shares of SomaLogic during the 4th quarter worth about $36,000. PNC Financial Services Group Inc. purchased a new position in shares of SomaLogic during the 3rd quarter worth about $37,000. UBS Group AG purchased a new position in shares of SomaLogic during the 3rd quarter worth about $58,000. Penserra Capital Management LLC purchased a new position in shares of SomaLogic during the 4th quarter worth about $98,000. Finally, Citadel Advisors LLC purchased a new position in shares of SomaLogic during the 3rd quarter worth about $129,000. 44.55% of the stock is currently owned by institutional investors.

About SomaLogic (Get Rating)

SomaLogic, Inc operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples.

Featured Stories

Get a free copy of the Zacks research report on SomaLogic (SLGC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for SomaLogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SomaLogic and related companies with MarketBeat.com's FREE daily email newsletter.